EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines

Alekxander Binderup, Andrea Galli, Nicolas Fossat, Carlota Fernandez-Antunez, Lotte S Mikkelsen, Lizandro René Rivera-Rangel, Troels K H Scheel, Ulrik Fahnøe, Jens Bukh, Santseharay Ramirez

Virology · 2023

DOI: 10.1016/j.virol.2023.06.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Virology, 2023. Verfasst von Alekxander Binderup und 9 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and…. Hauptthemen laut MEDLINE: Encephalitis, Tick-Borne, Yellow Fever, Encephalitis Viruses, Tick-Borne. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With no approved antiviral therapies, the continuous emergence and re-emergence of tick-borne encephalitis virus (TBEV) and yellow fever virus (YFV) is a rising concern. We performed head-to-head comparisons of the antiviral activity of available nucleos(t)ide analogs (nucs) using relevant human cell lines. Eight existing nucs inhibited TBEV and/or YFV with differential activity between cell lines and viruses. Remdesivir, uprifosbuvir and sofosbuvir were the most potent drugs against TBEV and YFV in liver cells, but they had reduced activity in neural cells, whereas galidesivir retained uniform activity across cell lines and viruses. Ribavirin, valopicitabine, molnupiravir and GS-6620 exhibited only moderate antiviral activity. We found antiviral activity for drugs previously reported as inactive, demonstrating the importance of using human cell lines and comparative experimental assays when screening the activity of nucs. The relatively high antiviral activity of remdesivir, sofosbuvir and uprifosbuvir against TBEV and YFV merits further investigation in clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalitis, Tick-BorneYellow FeverEncephalitis Viruses, Tick-BorneHumansSofosbuvirCell LineYellow fever virusAntiviral Agents

Stichwörter der Autor:innen

AntiviralsFlavivirusNucsRemdesivirRepurposed drugsSofosbuvirUprifosbuvir

Substanzen

SofosbuvirAntiviral Agents

Autor:innen und Institutionen

  • Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of C…

Zitieren

APA

Binderup, A., Galli, A., Fossat, N., Fernandez-Antunez, C., Mikkelsen, L. S., Rivera-Rangel, L. R., Scheel, T. K. H., Fahnøe, U., Bukh, J., & Ramirez, S. (2023). Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines. Virology. https://doi.org/10.1016/j.virol.2023.06.002

Vancouver

Binderup A, Galli A, Fossat N, Fernandez-Antunez C, Mikkelsen LS, Rivera-Rangel LR, et al. Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines. Virology. 2023. doi:10.1016/j.virol.2023.06.002

BibTeX
@article{Binderup2023,
  author = {Binderup, Alekxander and Galli, Andrea and Fossat, Nicolas and Fernandez-Antunez, Carlota and Mikkelsen, Lotte S and Rivera-Rangel, Lizandro René and Scheel, Troels K H and Fahnøe, Ulrik and Bukh, Jens and Ramirez, Santseharay},
  title = {Differential activity of nucleotide analogs against tick-borne encephalitis and yellow fever viruses in human cell lines},
  journal = {Virology},
  year = {2023},
  doi = {10.1016/j.virol.2023.06.002}
}
Kostenlos starten →